2,335 trials (keyword fallback)
Efficacy of the New CPRV
Primary: Rabies Neutralizing Antibodies Determine by Rapid Fluorescent Focus Inhibition Test (RFFIT) — 0; 0; 0 International unit per ml
Rabies · Communicable Disease · Virus Diseases
Primary: Rabies Virus Neutralizing Activity (RVNA) of Geometric Mean Concentration (GMC) at Study Day 8 — 4.346; 0.232 IU/mL
Rabies
Primary: Rabies Virus Neutralizing Activity (RVNA) of Geometric Mean Concentration (GMC) at Study Day 8 — 4.70; 0.13; 3.30; 0.17 IU/mL
Rabies (Healthy Volunteers)
Primary: Percentage of Participants With Rabies Virus Neutralizing Antibody (RVNA) Titers Greater Than or Equal to (>=) 0.5 International Units Per Milliliter…
Rabies · Healthy Volunteers
Primary: Primary Series Cohort 1: Percentage of Participants With Rabies Virus Neutralizing Antibody (RVNA) Titer Greater Than or Equal to (>=) 0.5 IU/mL — 100; 100; 100; 100…
Rabies Human
Primary: Antibody Titers — 217.39; 805.64 IU/mL
Rabies Infection
Primary: Percentages of Subjects With RVNA Titer >= 0.5 and Vaccine Group Differences ("4-sites, 1-week" to That of "2-sites, TRC" ID PEP Regimen of the PCEC Rabies Vaccine With…
Rabies
Primary: The Difference Between KamRAB and HRIG Comparator, in the Proportions of Subjects With Serum Anti-rabies IgG Antibody Concentration ≥ 0.5 IU/mL — 55; 58 Participants
Human Rabies
Primary: Percentage of Participants With Serum Rabies Virus Neutralizing Activity — 94.3; 97.1; 97.1; 100 percentage of participants — p=0.4187
Rabies
Primary: Number of Participants With a Boostability of the Rabies Antibodies After Booster Vaccination — 185; 183 Participants
Rabies
Primary: Geometric Mean Titer (GMT) 14 Days Post Fourth Dose Post Exposure Prophylaxis (PEP) With Purified Chick Embryo Cell Vaccine (PCECV) in Each Malaria Prophylaxis Group…
HIV · Rabies
Primary: Rabies Neutralizing Antibody Titers — 8.48 IU/ml
Malaria · Plasmodium Falciparum Malaria
Primary: Safety and Reactogenicity (SAEs and AEs) — 45; 53; 22; 37 Number of events
Rabies · Rabies Immunisation
Primary: Number and Percentage of Participants With Solicited Injection Site Reactogenicity Events in Each Treatment Arm and Overall — 3; 2; 0; 0 Participants
Rabies Virus
Primary: Rabies Virus Neutralizing Antibody (RVNA) Geometric Mean Titers (GMTs) Against Rabies Virus at Day 0 — 0.101; 0.100; 0.102; 0.101 international units per milliliter